The changing face of severe scleroderma in five patients.
Five cases from recent experience are reported to characterize the changing pattern of disease. With the introduction of potent antihypertensive agents, especially the angiotensin I-II converting enzyme inhibitors (CEI), the clinical pattern of scleroderma renal involvement has changed from an acute, oliguric, usually fatal renal failure to an indolent functional decline of the kidneys, heart and lungs together.
Spooner
M S
MS
Department of Medicine, Medical University of South Carolina, Charleston 29425.
LeRoy
E C
EC
D000284:Administration, Oral; D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004347:Drug Interactions; D005260:Female; D006321:Heart / Q000503:physiopathology; D006801:Humans; D007668:Kidney / Q000503:physiopathology; D008168:Lung / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012595:Scleroderma, Systemic / Q000188:drug therapy / Q000503:physiopathology*
D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers